{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T04:04:50Z","timestamp":1744085090867,"version":"3.40.3"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T00:00:00Z","timestamp":1741824000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T00:00:00Z","timestamp":1741824000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s40261-025-01429-8","type":"journal-article","created":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T01:44:15Z","timestamp":1741830255000},"page":"191-199","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Frequency of Acute Kidney Injury After the Initiation of Vitamin D Receptor Activators: A Multicenter Retrospective Observational Study"],"prefix":"10.1007","volume":"45","author":[{"given":"Masanori","family":"Nakanishi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8203-392X","authenticated-orcid":false,"given":"Tomohiro","family":"Mizuno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinya","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daiki","family":"Hira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takenao","family":"Koseki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Matsubara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Yokoi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Motoko","family":"Yanagita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohiro","family":"Terada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeki","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naotake","family":"Tsuboi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,13]]},"reference":[{"issue":"6","key":"1429_CR1","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1053\/j.ajkd.2017.07.019","volume":"70","author":"T Isakova","year":"2017","unstructured":"Isakova T, Nickolas TL, Denburg M, Yarlagadda S, Weiner DE, Guti\u00e9rrez OM, et al. KDOQI US commentary on the 2017 KDIGO clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Am J Kidney Dis. 2017;70(6):737\u201351.","journal-title":"Am J Kidney Dis"},{"issue":"7","key":"1429_CR2","volume":"13","author":"E Habas Sr","year":"2021","unstructured":"Habas E Sr, Eledrisi M, Khan F, Elzouki AY. Secondary hyperparathyroidism in chronic kidney disease: pathophysiology and management. Cureus. 2021;13(7): e16388.","journal-title":"Cureus"},{"issue":"6976","key":"1429_CR3","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1136\/bmj.310.6976.358","volume":"310","author":"NA Hamdy","year":"1995","unstructured":"Hamdy NA, Kanis JA, Beneton MN, Brown CB, Juttmann JR, Jordans JG, et al. Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure. BMJ. 1995;310(6976):358\u201363.","journal-title":"BMJ"},{"issue":"5","key":"1429_CR4","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1053\/j.ajkd.2004.01.012","volume":"43","author":"JW Coburn","year":"2004","unstructured":"Coburn JW, Maung HM, Elangovan L, Germain MJ, Lindberg JS, Sprague SM, et al. Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4. Am J Kidney Dis. 2004;43(5):877\u201390.","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"1429_CR5","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1681\/ASN.2013010103","volume":"25","author":"AY Wang","year":"2014","unstructured":"Wang AY, Fang F, Chan J, Wen YY, Qing S, Chan IH, et al. Effect of paricalcitol on left ventricular mass and function in CKD: the OPERA trial. J Am Soc Nephrol. 2014;25(1):175\u201386.","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"1429_CR6","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1038\/ki.1990.87","volume":"37","author":"S Rosen","year":"1990","unstructured":"Rosen S, Greenfeld Z, Bernheim J, Rathaus M, Podjarny E, Brezis M. Hypercalcemic nephropathy: chronic disease with predominant medullary inner stripe injury. Kidney Int. 1990;37(4):1067\u201375.","journal-title":"Kidney Int"},{"issue":"1","key":"1429_CR7","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1080\/0886022X.2019.1578667","volume":"41","author":"S Aihara","year":"2019","unstructured":"Aihara S, Yamada S, Oka H, Kamimura T, Nakano T, Tsuruya K, et al. Hypercalcemia and acute kidney injury induced by eldecalcitol in patients with osteoporosis: a case series of 32 patients at a single facility. Ren Fail. 2019;41(1):88\u201397.","journal-title":"Ren Fail"},{"issue":"6","key":"1429_CR8","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","volume":"53","author":"S Matsuo","year":"2009","unstructured":"Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53(6):982\u201392.","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"1429_CR9","doi-asserted-by":"crossref","first-page":"R204","DOI":"10.1186\/cc2872","volume":"8","author":"R Bellomo","year":"2004","unstructured":"Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P. Acute renal failure: definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care. 2004;8(4):R204\u201312.","journal-title":"Crit Care"},{"issue":"2","key":"1429_CR10","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1159\/000439146","volume":"131","author":"NM Selby","year":"2015","unstructured":"Selby NM, Hill R, Fluck RJ. Standardizing the early identification of acute kidney injury: the NHS England national patient safety alert. Nephron. 2015;131(2):113\u20137.","journal-title":"Nephron"},{"issue":"8","key":"1429_CR11","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1007\/s40620-024-02030-6","volume":"37","author":"R Aylward","year":"2024","unstructured":"Aylward R, Casula A, Tiffin N, Ben-Shlomo Y, Rayner B, Birnie K, et al. Consistency of alerts generated by, and implementation of, the NHS England acute kidney injury detection algorithm in English laboratories. J Nephrol. 2024;37(8):2317\u201325.","journal-title":"J Nephrol"},{"issue":"6","key":"1429_CR12","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1007\/s00774-023-01470-7","volume":"41","author":"K Ri","year":"2023","unstructured":"Ri K, Fukasawa T, Masuda S, Tanaka S, Takeuchi M, Yoshida S, et al. Frequency and determinants of serum calcium monitoring during eldecalcitol therapy in patients with osteoporosis. J Bone Miner Metab. 2023;41(6):890\u2013900.","journal-title":"J Bone Miner Metab"},{"issue":"4","key":"1429_CR13","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1007\/s00774-016-0779-2","volume":"35","author":"H Saito","year":"2017","unstructured":"Saito H, Kakihata H, Nishida Y, Yatomi S, Nihojima S, Kobayashi Y, et al. The safety and effectiveness profile of eldecalcitol in a prospective, post-marketing observational study in Japanese patients with osteoporosis: interim report. J Bone Miner Metab. 2017;35(4):456\u201363.","journal-title":"J Bone Miner Metab"},{"issue":"5","key":"1429_CR14","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1161\/HYPERTENSIONAHA.114.03748","volume":"64","author":"C Zoccali","year":"2014","unstructured":"Zoccali C, Curatola G, Panuccio V, Tripepi R, Pizzini P, Versace M, et al. Paricalcitol and endothelial function in chronic kidney disease trial. Hypertension. 2014;64(5):1005\u201311.","journal-title":"Hypertension"},{"issue":"9","key":"1429_CR15","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.2215\/CJN.10791016","volume":"12","author":"A Levin","year":"2017","unstructured":"Levin A, Tang M, Perry T, Zalunardo N, Beaulieu M, Dubland JA, et al. Randomized controlled trial for the effect of vitamin D supplementation on vascular stiffness in CKD. Clin J Am Soc Nephrol. 2017;12(9):1447\u201360.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"1429_CR16","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.bone.2011.07.011","volume":"49","author":"T Matsumoto","year":"2011","unstructured":"Matsumoto T, Ito M, Hayashi Y, Hirota T, Tanigawara Y, Sone T, et al. A new active vitamin D3 analog, eldecalcitol, prevents the risk of osteoporotic fractures: a randomized, active comparator, double-blind study. Bone. 2011;49(4):605\u201312.","journal-title":"Bone"},{"issue":"6","key":"1429_CR17","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s10157-024-02497-4","volume":"28","author":"Japanese Society of Nephrology","year":"2024","unstructured":"Japanese Society of Nephrology. Essential points from evidence-based clinical practice guideline for chronic kidney disease 2023. Clin Exp Nephrol. 2024;28(6):473\u201395.","journal-title":"Clin Exp Nephrol"},{"issue":"4","key":"1429_CR18","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/nrneph.2017.2","volume":"13","author":"LS Chawla","year":"2017","unstructured":"Chawla LS, Bellomo R, Bihorac A, Goldstein SL, Siew ED, Bagshaw SM, et al. Acute kidney disease and renal recovery: consensus report of the Acute Disease Quality Initiative (ADQI) 16 Workgroup. Nat Rev Nephrol. 2017;13(4):241\u201357.","journal-title":"Nat Rev Nephrol"},{"issue":"8","key":"1429_CR19","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.2215\/CJN.11290821","volume":"17","author":"MA Perazella","year":"2022","unstructured":"Perazella MA, Rosner MH. Drug-induced acute kidney injury. Clin J Am Soc Nephrol. 2022;17(8):1220\u201333.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"11","key":"1429_CR20","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1016\/j.ekir.2023.08.031","volume":"8","author":"RE Campbell","year":"2023","unstructured":"Campbell RE, Chen CH, Edelstein CL. Overview of antibiotic-induced nephrotoxicity. Kidney Int Rep. 2023;8(11):2211\u201325.","journal-title":"Kidney Int Rep."}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-025-01429-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-025-01429-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-025-01429-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T04:59:35Z","timestamp":1744001975000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-025-01429-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,13]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["1429"],"URL":"https:\/\/doi.org\/10.1007\/s40261-025-01429-8","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"type":"print","value":"1173-2563"},{"type":"electronic","value":"1179-1918"}],"subject":[],"published":{"date-parts":[[2025,3,13]]},"assertion":[{"value":"25 February 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No funding was received for the conduct of this study or the preparation of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Within 36 months, Shigeki Yamada has received honoraria from EA Pharma Co., Ltd. and Takeda Pharmaceutical Co., Ltd. Tomohiro Mizuno has received honoraria from Kyowa Kirin Co., Ltd. and Sumitomo Pharma Co., Ltd. Tomohiro Mizuno is an editorial board member of Clinical Drug Investigation. Tomohiro Mizuno was not involved in the selection of peer reviewers for the manuscript or in any of the subsequent editorial decisions.\u00a0Masanori Nakanishi, Shinya Sakai, Daiki Hira, Takenao Koseki, Takeshi Matsubara, Hideki Yokoi, Motoko Yanagita, Tomohiro Terada, and Naotake Tsuboi have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This research was approved by the ethics boards of Fujita Health University Hospital (ethics committee approval number: HM22-224) and Kyoto University Hospital (ethics committee approval number: R3634) and was conducted in accordance with the appropriate guidelines.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Because this was a retrospective cohort study, an opt-out approach for obtaining informed consent was used with the approval of the ethics board.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Data archiving is not mandated but data will be made available on reasonable request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"MN and TM contributed to the study conception and design, analyzed the data, and drafted the manuscript. MN, SS, and HD interpreted the data. SS and HD contributed to drafting the manuscript and the study design. TK, YM, HY, MY, TT, SY, and NT designed the study and reviewed the manuscript. All authors read and approved the final version.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}